Please login to the form below

Not currently logged in
Email:
Password:

John Thievon named president of Dey Pharma

Former CEO of MiddleBrook Pharmaceuticals to help lead Mylan's integrated speciality pharmaceutical division

Mylan has named John Thievon as president of its integrated speciality pharmaceutical business Dey Pharma.

Thievon joins from MiddleBrook Pharmaceuticals where he was president and CEO.

He has more than 20 years experience in the healthcare industry and while serving as Middlebrook's CEO he oversaw the US pharma company's expansion from 18 employees to 450 and subsequent takeover by Victory Pharma.

He also worked as executive vice president of commercial operations for Adams Respiratory Therapeutics and spent four years at IMS Health.

Mylan's president Heather Bresch said: “Dey has been, and continues to be, a very valuable asset and important growth driver for Mylan, evidenced by the strong performance of this business. John's appointment demonstrates our continued commitment to invest in Dey and strengthen what we have in place in order to support the continued success of this business into the future."

As president of Dey Pharma, Thievon will drive the company's focus on medicines to treat respiratory diseases, severe allergic reactions and psychiatric disorders.

21st December 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...